FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386018518> ?p ?o ?g. }

• W4386018518 endingPage "e93079e9" @default.
• W4386018518 startingPage "e93079e9" @default.
• W4386018518 abstract "Background: The toxic effects of induction chemotherapy for acute myeloid leukemia (AML) are only worth it if a patient responds. Until now, no validated scoring system can accurately predict patients’ responses to chemotherapy. Most prediction approaches are complicated as they utilize various cytogenetic and molecular abnormalities. This is not only imprecise but also time-consuming. Walter et al. used a scoring system with an area under the curve (AUC) of 0.64 to 0.69 to predict resistance to chemotherapy. Ng et al. incorporated mutational data with other covariates to get concordance statistics (C-statistics) of 0.65 to 0.8 in response prediction, which was biased because death and relapse affected the C-statistics. Machine learning (ML) aims to make accurate predictions based on existing data. Random Forest (RF) is an ML algorithm widely used to make predictions related to cancer, like progression and survival. In AML, RF has been recently applied in predicting patients’ overall survival (OS). It achieved a prediction efficiency of AUC 0.59 to 0.64, better than the ELN risk stratification. Therefore, we focused on predicting the response to induction therapy based on mutational data, as induction failure can worsen patients’ prognosis due to treatment delay and exposure to unnecessary toxicity. Aims: We applied ML to investigate whether targeted sequencing contained the relevant information to predict the patients’ response to induction chemotherapy. Methods: In this study, sequencing data of 111 genes of a cohort of 1552 AML patients from the AML NCRI study group were retrospectively analyzed using RF. Following intense induction chemotherapy, patients were stratified into responders achieving complete remission (CR) or resistant not achieving CR. The CR rate in our dataset was around 80%, matching rates reported in the literature. However, 47% of patients in the CR group relapsed during follow-up. Sequencing was performed on an Illumina platform. All analyses were done using R. The cohort was randomly split into training (70%) and test (30%) sets. Our starting dataset needed to be more balanced, having 80% CR vs. 20% resistance. Therefore, the training set was balanced using SMOTE before RF analysis. Results: As we aimed to distinguish responders from resistant patients, we first tested different relapse time thresholds to decide whether to include the relapsed patients in the CR or the resistant group. RF revealed that the best prediction accuracy could be obtained when all relapsed patients were included in the CR group. Patients who died within 28 days of starting therapy were excluded, as early death introduced bias to RF analysis. RF model with balanced data achieved 93% accuracy in predicting the training set (AUC 0.9). When the RF model was used to predict the treatment outcome of the test set (a new subset of data), it attained 79% accuracy, AUC 0.676, 87% sensitivity, 44% specificity, 86% positive predictive value (PPV), and 46% negative predictive. The effect of data balancing is reflected on the prediction of the test set (after balancing: accuracy increased from 73% to 79%, and specificity increased from 19% to 44%), resulting in higher prediction accuracy for the minority (resistant) group. Summary/Conclusion: Targeted sequencing data obtained during diagnosis include the information for RF to predict the patients’ response to induction chemotherapy. RF is a practical, rapidly developing algorithm that can be incorporated into future technologies to obtain high response prediction accuracy in AML patients Keywords: Induction chemotherapy, Acute myeloid leukemia, Prediction, Machine learning" @default.
• W4386018518 created "2023-08-21" @default.
• W4386018518 creator A5005531458 @default.
• W4386018518 creator A5024188669 @default.
• W4386018518 creator A5027257033 @default.
• W4386018518 creator A5030540382 @default.
• W4386018518 creator A5039812798 @default.
• W4386018518 creator A5070974589 @default.
• W4386018518 date "2023-08-01" @default.
• W4386018518 modified "2023-10-16" @default.
• W4386018518 title "P546: MACHINE LEARNING AND RESPONSE TO INDUCTION CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA" @default.
• W4386018518 doi "https://doi.org/10.1097/01.hs9.0000969092.93079.e9" @default.
• W4386018518 hasPublicationYear "2023" @default.
• W4386018518 type Work @default.
• W4386018518 citedByCount "0" @default.
• W4386018518 crossrefType "journal-article" @default.
• W4386018518 hasAuthorship W4386018518A5005531458 @default.
• W4386018518 hasAuthorship W4386018518A5024188669 @default.
• W4386018518 hasAuthorship W4386018518A5027257033 @default.
• W4386018518 hasAuthorship W4386018518A5030540382 @default.
• W4386018518 hasAuthorship W4386018518A5039812798 @default.
• W4386018518 hasAuthorship W4386018518A5070974589 @default.
• W4386018518 hasBestOaLocation W43860185181 @default.
• W4386018518 hasConcept C119043178 @default.
• W4386018518 hasConcept C119857082 @default.
• W4386018518 hasConcept C121608353 @default.
• W4386018518 hasConcept C126322002 @default.
• W4386018518 hasConcept C143998085 @default.
• W4386018518 hasConcept C160798450 @default.
• W4386018518 hasConcept C2776611710 @default.
• W4386018518 hasConcept C2776694085 @default.
• W4386018518 hasConcept C2778041864 @default.
• W4386018518 hasConcept C2778729363 @default.
• W4386018518 hasConcept C41008148 @default.
• W4386018518 hasConcept C58471807 @default.
• W4386018518 hasConcept C71924100 @default.
• W4386018518 hasConcept C72563966 @default.
• W4386018518 hasConcept C76318530 @default.
• W4386018518 hasConceptScore W4386018518C119043178 @default.
• W4386018518 hasConceptScore W4386018518C119857082 @default.
• W4386018518 hasConceptScore W4386018518C121608353 @default.
• W4386018518 hasConceptScore W4386018518C126322002 @default.
• W4386018518 hasConceptScore W4386018518C143998085 @default.
• W4386018518 hasConceptScore W4386018518C160798450 @default.
• W4386018518 hasConceptScore W4386018518C2776611710 @default.
• W4386018518 hasConceptScore W4386018518C2776694085 @default.
• W4386018518 hasConceptScore W4386018518C2778041864 @default.
• W4386018518 hasConceptScore W4386018518C2778729363 @default.
• W4386018518 hasConceptScore W4386018518C41008148 @default.
• W4386018518 hasConceptScore W4386018518C58471807 @default.
• W4386018518 hasConceptScore W4386018518C71924100 @default.
• W4386018518 hasConceptScore W4386018518C72563966 @default.
• W4386018518 hasConceptScore W4386018518C76318530 @default.
• W4386018518 hasIssue "S3" @default.
• W4386018518 hasLocation W43860185181 @default.
• W4386018518 hasOpenAccess W4386018518 @default.
• W4386018518 hasPrimaryLocation W43860185181 @default.
• W4386018518 hasRelatedWork W1601684588 @default.
• W4386018518 hasRelatedWork W2007442696 @default.
• W4386018518 hasRelatedWork W2077634565 @default.
• W4386018518 hasRelatedWork W2104328188 @default.
• W4386018518 hasRelatedWork W2108427450 @default.
• W4386018518 hasRelatedWork W2366898313 @default.
• W4386018518 hasRelatedWork W2796075800 @default.
• W4386018518 hasRelatedWork W3048802245 @default.
• W4386018518 hasRelatedWork W4385708664 @default.
• W4386018518 hasRelatedWork W648938440 @default.
• W4386018518 hasVolume "7" @default.
• W4386018518 isParatext "false" @default.
• W4386018518 isRetracted "false" @default.
• W4386018518 workType "article" @default.